Cargando…
Medicaid coverage practices for approved gene and cell therapies: Existing barriers and proposed policy solutions
The current Medicaid system is ill equipped to handle the anticipated approvals of new gene and cell therapy products. These advanced therapies tend to be single-dose, potentially durable options for a variety of indications spanning oncology, rare disease, and more. The up-front cost of these thera...
| Autores principales: | , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
American Society of Gene & Cell Therapy
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10242491/ https://www.ncbi.nlm.nih.gov/pubmed/37287748 http://dx.doi.org/10.1016/j.omtm.2023.05.015 |